MaxCyte, Inc. Total Voting Rights (9363Q)
March 03 2021 - 01:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9363Q
MaxCyte, Inc.
03 March 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Gaithersburg, Maryland - 3 March 2021: MaxCyte (LSE: MXCT, MXCL,
MXCN), the global cell-based medicines and life sciences company,
announces that pursuant to its block admission facility, details of
which were announced on 2 May 2017, it has recently issued 3,300
shares of common stock, $0.01 par, of the Company ("Common Stock")
in satisfaction of the exercise of share options.
The new Common Stock will rank pari passu with the existing
shares of common stock of the Company. The total issued stock
capital of the Company, as at 28 February 2021, following the
recent issue of the new Common Stock, is 84,559,246 shares of
Common Stock. Shareholders in the Company may use this figure as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 74,329,157 ; the number of restricted shares
of Common Stock trading under the symbol 'MXCL' is 9,900,089 a nd
the number of restricted shares of Common Stock trading under the
symbol 'MXCN' will be 330,000.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering platform
technologies that drives the next--generation of cell and
gene-editing therapies. The Company's technology, which is designed
to make a meaningful difference for patients, is deployed by
leading drug developers worldwide, including all of the top ten
global biopharmaceutical companies. MaxCyte licenses have been
granted for more than 140 cell therapy programs, with more than 100
licensed for clinical use, and the Company has now entered into 12
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998 and is
headquartered in Gaithersburg, Maryland, US.
For more information, visit www.maxcyte.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKBBNKBKBCNK
(END) Dow Jones Newswires
March 03, 2021 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Mar 2023 to Mar 2024